This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-sta...
Plus, news about X4 Pharmaceuticals, Viracta Therapeutics, Crown Laboratories, Q...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of...
AstraZeneca has terminated all development of vemircopan, the oral factor D inhi...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...
We’re in dealmaking season for publicly traded digital health companies. In ...
A trade group representing 1,600 hospitals says 340B rebate models proposed by m...
Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech f...
Personify Health, which sells healthcare spending management services to employe...
After promoting its oncology officer Chris Boshoff to chief scientific officer l...
Bristol Myers Squibb is ending work on a handful of assets, including an immunol...
After running into clinical hurdles with its “diamond in the rough” strategy, Lo...
Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsiz...
→ Francisco Ballester is retiring as president, region international at Sandoz o...
Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in ...
The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical busine...